These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12002721)

  • 1. Kidney failure after treatment with 90Y-DOTATOC.
    Schumacher T; Waldherr C; Mueller-Brand J; Maecke H
    Eur J Nucl Med Mol Imaging; 2002 Mar; 29(3):435. PubMed ID: 12002721
    [No Abstract]   [Full Text] [Related]  

  • 2. 90Y-DOTATOC and nephrotoxicity.
    Otte A; Cybulla M; Weiner SM
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1543. PubMed ID: 12537003
    [No Abstract]   [Full Text] [Related]  

  • 3. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy.
    Moll S; Nickeleit V; Mueller-Brand J; Brunner FP; Maecke HR; Mihatsch MJ
    Am J Kidney Dis; 2001 Apr; 37(4):847-51. PubMed ID: 11273886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. End-stage renal disease after treatment with 90Y-DOTATOC.
    Cybulla M; Weiner SM; Otte A
    Eur J Nucl Med; 2001 Oct; 28(10):1552-4. PubMed ID: 11685499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.
    Bodei L; Cremonesi M; Grana C; Rocca P; Bartolomei M; Chinol M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):1038-46. PubMed ID: 15150675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid).
    Davì MV; Bodei L; Francia G; Bartolomei M; Oliani C; Scilanga L; Reghellin D; Falconi M; Paganelli G; Lo Cascio V; Ferdeghini M
    J Endocrinol Invest; 2006 Jun; 29(6):563-7. PubMed ID: 16840837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors.
    Forrer F; Waldherr C; Maecke HR; Mueller-Brand J
    Anticancer Res; 2006; 26(1B):703-7. PubMed ID: 16739341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe?
    Cybulla M; Weiner SM; Otte A
    Med Sci Monit; 2002 Apr; 8(4):LE7. PubMed ID: 11951054
    [No Abstract]   [Full Text] [Related]  

  • 9. [Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].
    Otte A; Herrmann R; Mäcke HR; Müller-Brand J
    Praxis (Bern 1994); 1999 Aug; 88(31-32):1263-8. PubMed ID: 10479965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
    Bushnell D; Menda Y; O'Dorisio T; Madsen M; Miller S; Carlisle T; Squires S; Kahn D; Walkner W; Connolly M; O'Dorisio S; Karwal M; Ponto J; Bouterfa H
    Cancer Biother Radiopharm; 2004 Feb; 19(1):35-41. PubMed ID: 15068609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impairment of lymphocyte function following yttrium-90 DOTATOC therapy.
    Barsegian V; Hueben C; Mueller SP; Poeppel TD; Horn PA; Bockisch A; Lindemann M
    Cancer Immunol Immunother; 2015 Jun; 64(6):755-64. PubMed ID: 25822768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients.
    Paganelli G; Zoboli S; Cremonesi M; Mäcke HR; Chinol M
    Cancer Biother Radiopharm; 1999 Dec; 14(6):477-83. PubMed ID: 10850334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
    Förster GJ; Engelbach MJ; Brockmann JJ; Reber HJ; Buchholz HG; Mäcke HR; Rösch FR; Herzog HR; Bartenstein PR
    Eur J Nucl Med; 2001 Dec; 28(12):1743-50. PubMed ID: 11734910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid.
    Merola E; Capurso G; Campana D; Panzuto F; Monarca B; Tomassetti P; Delle Fave G
    Dig Liver Dis; 2010 Jun; 42(6):457-8. PubMed ID: 19783489
    [No Abstract]   [Full Text] [Related]  

  • 15. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.
    Bodei L; Handkiewicz-Junak D; Grana C; Mazzetta C; Rocca P; Bartolomei M; Lopera Sierra M; Cremonesi M; Chinol M; Mäcke HR; Paganelli G
    Cancer Biother Radiopharm; 2004 Feb; 19(1):65-71. PubMed ID: 15068613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is radiation nephropathy caused by yttrium-90?
    Otte A; Weiner SM; Cybulla M
    Lancet; 2002 Mar; 359(9310):979; author reply 979. PubMed ID: 11918946
    [No Abstract]   [Full Text] [Related]  

  • 17. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study.
    Bodei L; Cremonesi M; Zoboli S; Grana C; Bartolomei M; Rocca P; Caracciolo M; Mäcke HR; Chinol M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):207-16. PubMed ID: 12552338
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Menda Y; Madsen MT; O'Dorisio TM; Sunderland JJ; Watkins GL; Dillon JS; Mott SL; Schultz MK; Zamba GKD; Bushnell DL; O'Dorisio MS
    J Nucl Med; 2018 Nov; 59(11):1692-1698. PubMed ID: 29523629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide.
    Paganelli G; Zoboli S; Cremonesi M; Bodei L; Ferrari M; Grana C; Bartolomei M; Orsi F; De Cicco C; Mäcke HR; Chinol M; de Braud F
    Eur J Nucl Med; 2001 Apr; 28(4):426-34. PubMed ID: 11357492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
    Waldherr C; Pless M; Maecke HR; Schumacher T; Crazzolara A; Nitzsche EU; Haldemann A; Mueller-Brand J
    J Nucl Med; 2002 May; 43(5):610-6. PubMed ID: 11994522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.